Since the identification of activating oncogenic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) in 2004 [2], an increasing number of activating oncogene alterations have been identified in NSCLC, with a related growing knowledge of their impact on treatment selection and survival [3,4]. Here, EGFR is linked to non-small cell lung carcinoma.